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LETTERS TO THE EDITOR
Topical Retinoids:
Another Piece for the
Retinoid-Cigarette-
Lung Cancer Puzzle?
To the Editor:
The possibility of a role for topical
retinoids might add an additional piece
to the retinoid-cigarette-lung cancer
puzzle.1
A poster2 at the 2005 annual meet-
ing of The Society for Investigative Der-
matology described the halting of a top-
ical retinoid study because of an excess
of deaths from lung cancer and pulmo-
nary disease in the treated group. A
10-center, 1131-participant trial had
been sponsored by the Department of
Veterans Affairs to study the ability of
0.1% tretinoin cream to reduce the de-
velopment of keratinocyte carcinoma.
Participants (average age, 71 years) ap-
plied tretinoin cream or placebo to their
face and ears every day for 6 years. The
study was stopped 6 months before
completion because of deaths from pul-
monary disease (12 versus two) and
non-small cell lung cancer (11 versus 4)
but not other cancers (20 versus 18) or
cardiac disease (19 versus 16) in the
tretinoin cream versus placebo groups.
Presenters of the poster suggested
that failure to randomize for factors such
as smoking had flawed the study design.
With further analysis, they found differ-
ences in Charlson comorbidity index,
age, and smoking. Each of those differ-
ences favored worse prognosis in the
tretinoin group, but all differences were
small and statistically insignificant. Cox
multivariate regression with those vari-
ables and treatment group revealed that,
with joint consideration of all of those
variables, the mortality difference be-
tween the groups was not statistically
significant.
The authors concluded that treti-
noin did not cause the mortality differ-
ence between the groups and that, in
retrospect, the termination of the inter-
vention was unnecessary. They did not
consider the possibility that absorbed
tretinoin might have acted like dietary
carotinoid in cigarette smokers.
A possible mechanism for such an
effect was described in 2004 by Harder
et al.3 from Kiel and Stockholm. They
added tretinoin to foreskin keratinocytes
in cell culture and looked for an effect
on the synthesis of beta-defensins. There
was a profound reduction in defensins-1,
-2, -3, and -4. Their conclusion was that
retinoic acid “might downregulate the
innate chemical defense system of hu-
man skin.”
Like the skin, the bronchial epi-
thelium confronts the environment and,
like the skin, uses defensins as part of its
innate immune response capability.4
Bronchial defensins are increased in squa-
mous metaplasia and in lung cancer.
By reducing the defensin effect,
absorbed topical retinoid could be re-
sponsible for an increase in the appear-
ance of lung cancer without the need to
postulate a carcinogenic mechanism. The
same explanation would account for the
excess of deaths from non-malignant pul-
monary disease in the halted VA trial.
Whether enough tretinoin is ab-
sorbed from topical application to affect
the bronchial production of defensins or
other agents of innate immunity needs to
be investigated. The Renova (OrthoNeu-
trogena, Raritan, NJ) package insert de-
scribes the systemic absorption of treti-
noin as ranging from 1% to 31%
depending on the condition of the af-
fected skin, although a study from The
Johnson and Johnson Skin Research
Center reported that plasma levels of
tretinoin were not significantly different
from pretreatment levels even after
chronic use.5
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Temozolomide as
Prophylaxis for Brain
Metastasis in Non-small
Cell Lung Cancer
To the Editor:
We read with interest the article
by Choong et al.1 regarding the use of
temozolomide and irinotecan in non-
small cell lung cancer (NSCLC) with
particular attention to the development
of brain metastasis. They suggested that
temozolomide had “little role in the pro-
phylaxis against metastasis in NSCLC”
based on their results. They observed
only three of 37 patients developing
brain metastasis in this phase II study.
(Nine patients entered the study with a
history of radiation-treated brain metas-
tasis; the patients had no clinical evi-
dence of central nervous system (CNS)
progression while on study.) As 50% of
patients with NSCLC would be ex-
pected to develop brain metastasis (with
median time to development of 6–9
months), we came to a different conclu-
sion. In this regard, in a prospective trial
of well-staged (including head magnetic
resonance imaging) stage IIIA and IIIB
NSCLC that we reported,2 20 of 25
patients treated with combined modality
therapy relapsed within less than 12
months, and of these, eight patients
(40% of all relapsing patients, 32% ofBoth authors hold rights to an applied-for patent for
a non-retinoid anti-wrinkle product distributed
by Flinn Laboratories, Inc., Memphis, TN.
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